AELIX Therapeutics

Hong Kong-based Immuno Cure BioTech has emerged as one of the few Chinese biotechs to tap into the potential of therapeutic DNA vaccines to achieve the immune-based functional cure of HIV/AIDS through

Gilead Sciences, Inc. secured the dominant position in HIV therapy years ago, but maintaining that lead has taken an aggressive research and development effort aimed at optimizing current therapy for

Having just seen portfolio company Sanifit Therapeutics S.A. snapped up by Vifor Pharma Group , constituting the largest acquisition in the Spanish biotech sector over the past few years, Pablo Ci

Barcelona, Spain-based AELIX Therapeutics ’s proprietary T-cell immunogen has shown a signal of therapeutic benefit in an early clinical study, and the biotech is now aiming to raise series B financi